Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
https://doi.org/10.37489/2588-0519-2020-S4-23-27
Abstract
No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable in such patients in life-threatening situations, when interleukin-6 blockers (tocilizumab, sarilumab) are unavailable.
About the Authors
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
Yu. Yu. Kiselev
Oslo Metropolitan University
Norway
Norway
Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet.
Oslo
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. Gosudarstvennyj reestr lekarstvennyh sredstv. Instrukciya po medicinskomu primeneniyu. (In Russ). Доступно по: URL: http://grls.rosminzdrav.ru/grls.aspx (дата обращения: 14.05.2020).
2. Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016;149:1294-301. DOI: 10.1016/j.chest.2015.11.004
3. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-528. DOI:10.1007/s00281-017-0639-8
4. Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829-840. DOI:10.1007/s00134-015-4095-4
5. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.
6. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
7. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2016;3:CD010406.
8. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. The Journal of Heart and Lung Transplantation. 2020. [In Press]. Available at: https://www.jhltonline.org/article/S1053-2498(20)31473-X/fulltext
9. China National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment. Seventh Edition. 2020. Available at: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html.
10. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684.
11. Liu Y, Sun W, Li J, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv 2020. DOI: 10.1101/2020.02.17.20024166
12. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;e200994. DOI:10.1001/jamainternmed.2020.0994
13. Wang Y, Jiang W, He Q, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv 2020. [Preprint]. Available at: https://www.medrxiv.org/content/10.1101/2020.03.06.20032342v1.
14. Sun F, Kou H, Wang S, et al. Medication patterns and disease progression among 165 patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study. Preprints with the Lancet. 2020. [Preprint]. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551323
15. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475.
16. For Critically Ill Patients with COVID-19 (COVID-19 Treatment Guidelines Panel. Coronavirus Diseases 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed 11.05.2020.
17. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) CDC INFORMATION https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed 11.05.2020.
18. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https://www.idsociety.org/COVID19guidelines. Accessed 11.05.2020.
19. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 11.05.2020.
20. Vademecum per la cura delle persone con malattia da COVI-19. Edizione 2.0, 13 marzo 2020. Available at: http://www.simit.org/medias/1569-covid19-vademecum-13-03-202.pdf. Accessed 11.05.2020.
21. MM TREATMENT GUIDE FOR CRITICALLY ILL PATIENTS WITH COVID-19. Available at: https://med.umich.edu/surgery/mcccn/documents/MM-COVID-19-GUIDE-FINAL-3-29-2020.pdf. Accessed 11.05.2020.
22. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684. DOI:10.1016/S0140-6736(20)30361-5
23. Yale School Of Medicine. COVID-19 Treatment Algorithm. Available at: https://files-profile.medicine.yale.edu/documents/e91b4e5c-ae56-4bf18d5f-e674b6450847. Accessed 11.05.2020.
24. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ 2020. DOI: 10.1503/cmaj.200648; early-released April 29, 2020
25. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis [published online ahead of print, 2020 May 5]. Leukemia. 2020;1-9. DOI:10.1038/s41375-020-0848-3
Review
For citations:
Mirzaev K.B., Kiselev Yu.Yu., Sychev D.A. Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):23-27. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-23-27
Views:
4864
Email this article 